MRTX [NASD]
Mirati Therapeutics, Inc.
Index- P/E- EPS (ttm)-11.90 Insider Own0.80% Shs Outstand55.47M Perf Week1.88%
Market Cap3.60B Forward P/E- EPS next Y-12.78 Insider Trans-3.38% Shs Float52.20M Perf Month71.42%
Income-634.50M PEG- EPS next Q-3.49 Inst Own- Short Float9.03% Perf Quarter-19.32%
Sales72.80M P/S49.50 EPS this Y-40.90% Inst Trans1.06% Short Ratio3.23 Perf Half Y-53.45%
Book/sh22.52 P/B2.98 EPS next Y9.20% ROA-45.20% Target Price120.77 Perf Year-58.44%
Cash/sh24.71 P/C2.72 EPS next 5Y- ROE-52.20% 52W Range32.96 - 195.99 Perf YTD-54.24%
Dividend- P/FCF- EPS past 5Y-21.70% ROI-41.30% 52W High-64.18% Beta1.16
Dividend %- Quick Ratio10.90 Sales past 5Y- Gross Margin- 52W Low112.99% ATR5.02
Employees413 Current Ratio10.90 Sales Q/Q-82.50% Oper. Margin- RSI (14)63.48 Volatility5.88% 8.25%
OptionableYes Debt/Eq0.00 EPS Q/Q-27.10% Profit Margin- Rel Volume0.36 Prev Close67.13
ShortableYes LT Debt/Eq0.00 EarningsMay 04 AMC Payout- Avg Volume1.46M Price70.20
Recom2.10 SMA2020.96% SMA5019.28% SMA200-37.00% Volume471,777 Change4.57%
Jun-07-22Upgrade JMP Securities Mkt Perform → Mkt Outperform $72
May-20-22Upgrade Guggenheim Neutral → Buy $115
Feb-01-22Upgrade BofA Securities Underperform → Neutral $171 → $141
Nov-19-21Initiated BMO Capital Markets Outperform $187
Sep-23-21Initiated Stifel Buy $202
Aug-26-21Initiated Morgan Stanley Equal-Weight $160
Jun-04-21Upgrade Citigroup Neutral → Buy
May-17-21Downgrade Oppenheimer Outperform → Perform
May-10-21Upgrade Jefferies Hold → Buy $208 → $196
Apr-26-21Resumed Credit Suisse Outperform $285
Dec-08-20Initiated JMP Securities Mkt Perform
Dec-08-20Initiated Evercore ISI Outperform
Nov-17-20Downgrade BofA Securities Neutral → Underperform $196
Nov-10-20Downgrade Jefferies Buy → Hold $206 → $208
Nov-10-20Downgrade Guggenheim Buy → Neutral $230
Nov-09-20Reiterated H.C. Wainwright Buy $233 → $265
Sep-28-20Initiated BofA Securities Neutral $172
Sep-18-20Downgrade Citigroup Buy → Neutral $127 → $183
May-01-20Upgrade JP Morgan Neutral → Overweight $116
Apr-16-20Initiated Goldman Buy $151
Jun-30-22 01:08PM  
Jun-09-22 04:40PM  
10:43AM  
Jun-08-22 01:20PM  
11:45AM  
Jun-07-22 07:21PM  
04:04PM  
12:33PM  
Jun-06-22 08:43AM  
08:00AM  
08:00AM  
Jun-03-22 11:31AM  
May-29-22 08:21AM  
May-27-22 04:11PM  
02:39PM  
09:57AM  
May-26-22 05:00PM  
05:00PM  
May-25-22 04:30PM  
May-20-22 02:17PM  
May-19-22 04:30PM  
May-16-22 04:30PM  
May-05-22 02:14PM  
May-04-22 04:01PM  
Apr-27-22 04:30PM  
Apr-20-22 04:30PM  
Apr-06-22 03:26PM  
Mar-30-22 11:30AM  
Mar-21-22 08:25AM  
Mar-11-22 12:06PM  
Mar-07-22 09:00AM  
Mar-02-22 04:30PM  
Mar-01-22 07:52AM  
Feb-28-22 04:01PM  
Feb-25-22 08:34AM  
Feb-24-22 07:55AM  
Feb-21-22 03:00PM  
Feb-17-22 11:55AM  
Feb-16-22 04:13PM  
02:24PM  
08:21AM  
04:40AM  
Feb-15-22 04:15PM  
Feb-14-22 07:30AM  
Feb-07-22 09:59AM  
Feb-04-22 05:05PM  
Feb-03-22 04:35PM  
Feb-02-22 04:30PM  
Feb-01-22 05:35PM  
Jan-25-22 05:38PM  
Jan-21-22 01:11PM  
12:14PM  
10:00AM  
Jan-20-22 04:54AM  
Jan-14-22 02:18PM  
08:27AM  
Jan-10-22 10:19AM  
Jan-04-22 04:30PM  
Dec-29-21 06:51PM  
Dec-23-21 07:38AM  
Dec-13-21 11:38PM  
Dec-08-21 06:38PM  
Dec-07-21 04:38PM  
03:47PM  
Nov-23-21 04:30PM  
08:53AM  
Nov-22-21 07:30AM  
Nov-18-21 10:13AM  
Nov-17-21 07:30AM  
Nov-15-21 11:20AM  
Nov-10-21 09:11PM  
Nov-09-21 04:23PM  
11:00AM  
09:00AM  
Nov-08-21 05:25PM  
04:01PM  
12:44PM  
Nov-05-21 05:15PM  
Nov-04-21 04:41AM  
Nov-02-21 08:47AM  
Nov-01-21 04:30PM  
02:33PM  
02:30PM  
02:05PM  
12:47PM  
Oct-27-21 03:03PM  
Oct-07-21 04:30PM  
Oct-04-21 04:30PM  
01:59PM  
Sep-24-21 04:15PM  
Sep-20-21 04:09PM  
12:09PM  
11:44AM  
09:45AM  
09:38AM  
09:19AM  
09:12AM  
08:20AM  
07:55AM  
07:55AM  
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; and Sitravatinib, an investigational spectrum-selective kinase inhibitor that is in Phase 3 clinical trial for the treatment of NSCL cancer, as well as a KRAS G12D inhibitor program, which is in preclinical development. It has a collaboration and license agreement with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib. Mirati Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Christensen JamieEVP, Chief Scientific OfficerMay 23Sale63.5462439,64986,804Jun 14 04:35 PM
Cherrington Julie MDirectorJan 19Sale116.071,475171,2032,546Jan 20 04:57 PM
BAUM CHARLES MPresident,Founder,Head of R&DJan 18Option Exercise27.003,70399,981130,416Jan 18 08:32 PM
REED VICKIE SSVP, Chief Accounting OfficerJan 18Sale120.4853364,21715,369Jan 18 08:34 PM
Hickey BenjaminEVP, Chief Commercial OfficerJan 18Sale120.4862775,54334,976Jan 18 08:32 PM
BAUM CHARLES MPresident,Founder,Head of R&DJan 18Sale120.482,517303,253127,899Jan 18 08:32 PM
Christensen JamieEVP, Chief Scientific OfficerJan 18Sale120.5162775,55887,428Jan 18 08:33 PM
Hickey BenjaminEVP, Chief Commercial OfficerJan 07Sale135.941,964266,98424,848Jan 07 08:27 PM
REED VICKIE SSVP, Chief Accounting OfficerJan 07Sale135.9434546,90010,525Jan 07 08:26 PM
BAUM CHARLES MPresident,Founder,Head of R&DJan 04Sale147.754,114607,855101,170Jan 06 04:51 PM
REED VICKIE SSVP, Chief Accounting OfficerJan 04Sale147.74758111,98710,870Jan 06 04:50 PM
Christensen JamieEVP, Chief Scientific OfficerJan 04Sale147.721,442213,01777,300Jan 06 04:51 PM
Christensen JamieEVP, Chief Scientific OfficerDec 06Sale130.791,201157,07859,505Dec 07 05:52 PM
BAUM CHARLES MPresident & Head of R&DDec 03Option Exercise8.4947,204400,762159,918Dec 03 08:09 PM
BAUM CHARLES MPresident & Head of R&DDec 03Sale133.2047,2046,287,687112,714Dec 03 08:09 PM